A double-masked three-month comparison between 0.25% betaxolol suspension and 0.5% betaxolol ophthalmic solution.

Abstract

In 352 patients with primary open-angle glaucoma or ocular hypertension, a multicenter double-masked, parallel-group clinical study compared the effects on intraocular pressure and ocular comfort of 0.5% betaxolol ophthalmic solution, a cardioselective beta-adrenergic blocking agent, with 0.25% betaxolol suspension. With twice-daily dosages, baseline intraocular pressure was significantly reduced (P = .0005), with no significant difference between the two groups, at Week 2 and at Months 1, 2, and 3. Further, the prevalence of ocular discomfort upon topical instillation was significantly lower for 0.25% betaxolol suspension than for 0.5% betaxolol solution (P = .0005).

• Authors: R N Weinreb, D R Caldwell, S M Goode, B L Horwitz, R Laibovitz, C E Shrader, R H Stewart, A T Williams
• Journal: American journal of ophthalmology (Am J Ophthalmol) Vol. 110 Issue 2 Pg. 189-92 (Aug 15 1990) ISSN: 0002-9394 [Print] United States
• PMID: 2198812 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Ophthalmic Solutions
• Suspensions
• Betaxolol

Topics

• Administration, Topical
• Analysis of Variance
• Betaxolol (administration & dosage, adverse effects, therapeutic use)
• Dose-Response Relationship, Drug
• Double-Blind Method
• Female
• Glaucoma, Open-Angle (drug therapy)
• Humans
• Intraocular Pressure (drug effects)
• Male
• Middle Aged
• Multicenter Studies as Topic
• Ocular Hypertension (drug therapy)
• Ophthalmic Solutions (administration & dosage, therapeutic use)
• Randomized Controlled Trials as Topic
• Suspensions (administration & dosage, therapeutic use)